Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287063 · ClinicalTrials.gov registry record
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- 6
- Enrollment target
NCT03287063: Clinical Trial study, sponsored by University of Michigan Rogel Cancer Center.
NCT03287063 is a clinical trial that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03287063 was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to assess initial GBM heterogeneity by performing histological and genomic analysis of biopsies targeted by advanced MRI before treatment.
Interventions
- OTHER Tumor Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2020-03-23 |
Why NCT03287063 stopped before completion
NCT03287063 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tumor Biopsy is the first listed.
NCT03287063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03287063 about?
NCT03287063 is a clinical study titled "Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma". Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to ass...
What is the current status of trial NCT03287063?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2018-07-05. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT03287063?
The interventions under investigation include: Tumor Biopsy (OTHER).
Who is sponsoring clinical trial NCT03287063?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI